Page 474 - 73_04

N. VÍCTOR JIMÉNEZ TORRES Y COLS. ANAL. REAL ACAD. NAC. FARM.

(22) vanced or metastatic non-small-cell lung cancer: a phase III study addressing
the case for cisplatin. Ann. Oncol. 16: 602-610.
(23) GRIDELLI, C.; GALLO, C.; SHEPHERD, F.A.; ILLIANO, A.; PIANTEDOSI, F.; ROBBIATI,
(24) S.F.; MANZIONE, L.; BARBERA, S.; FRONTINI, L.; VELTRI, E.; FINDLAY, B.; CIGOLARI,
(25) S.; MYERS, R.; IANNIELLO, G.P.; GEBBIA, V.; GASPARINI, G.; FAVA, S.; HIRSH, V.;
(26) BEZJAK, A.; SEYMOUR, L. Y PERRONE, F. (2003) Gemcitabine plus vinorelbine
(27) compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for
(28) advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN
Investigators and the National Cancer Institute of Canada Clinical Trials
(29) Group. J. Clin. Oncol. 21: 3025-3034.
(30) D’ADDARIO, G.; PINTILIE, M.; LEIGHL, N.B.; FELD, R.; CERNY, T. Y SHEPHERD, F.A.
(31) (2005) Platinum-based versus non-platinum-based chemotherapy in advan-
ced non-small-cell lung cancer: a meta-analysis of the published literature. J.
Clin. Oncol. 23: 2926-2936.
PUJOL, J.L.; BARLESI, F. Y DAURES, J.P. (2006) Should chemotherapy combina-
tions for advanced non-small cell lung cancer be platinum-based? A meta-
analysis of phase III randomized trials. Lung Cancer. 51: 335-345.
AUTORES NO LISTADOS (1999) Effects of vinorelbine on quality of life and sur-
vival of elderly patients with advanced non-small-cell lung cancer. The Elder-
ly Lung Cancer Vinorelbine Italian Study Group. J. Natl. Cancer Inst. 91 (1):
66-72.
SCHILLER, J.A.; HARRINGTON, D.; VELAN, C.P.; LANGER, C.; SANDLER, A.; KROOK, J.;
ZHU, J. Y JOHNSON, D.H. EASTERN COOPERATIVE ONCOLOGY GROUP. (2002) Compa-
rison of four chemotherapy regimens for advanced non-small-call lung can-
cer. N. Eng.l J. Med. 346: 92-98.
NOVELLO, S.; LONGO, M. Y GIAJ, M. (2007) Toward Therapies Tailored to Pa-
tients Characteristics. J. Thorac. Oncol. 2: 38-41.
HERBST, R.S.; PRAGER, D.; HERMANN, R. FEHRENBACHER, L.; JOHNSON, B.E.; SAN-
DLER, A.; KRIS, M.G.; TRAN, H.T.; KLEIN, P.; LI, X.; RAMIES, D.; JOHNSON, D.H.
Y MILLER, V.A. TRIBUTE INVESTIGATOR GROUP. (2005) TRIBUTE: a phase III
trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and
paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin.
Oncol .23: 5892-5899.
GATZEMEIER, U.; PLUZANSKA, A.; SZCZESNA, A. (2004) Results of a phase III trial
of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemo-
therapy in advanced non-small cell lung cancer (NSCLC). Program and abs-
tracts of the 40th Annual Meeting of the American Society of Clinical Onco-
logy; June 5-8; New Orleans, Louisiana. Abstract 7010.
MILLER, V.A.; HERBST, R.S. Y PRAGER, D. (2004) Long survival of never smoking
non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl
(OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. Program and
abstracts of the 40th Annual Meeting of the American Society of Clinical
Oncology; June 5-8, New Orleans, Louisiana. Abstract 7061.
GIACCONE, G.; HERBST, R.S. MANEGOLD, C. SCAGLIOTTI, G.; ROSELL, R.; MILLER, V.;
NATALE, R.B.; SCHILLER, J.H.; VON PAWEL, J.; PLUZANSKA, A.; GATZEMEIER, U.;
GROUS, J.; OCHS, J.S.; AVERBUCH, S.D.; WOLF, M.K.; RENNIE, P.; FANDI, A. Y

1284